Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

MAIN PURPOSE: Voreloxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, inducing site-selective DNA damage. Voreloxin is in clinical studies, as a single agent and in combination with cytarabine, for the treatment of acute myeloid leukemia (AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Scatena, Caroline D., Kumer, Jeffrey L., Arbitrario, Jennifer P., Howlett, Anthony R., Hawtin, Rachael E., Fox, Judith A., Silverman, Jeffrey A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921053/
https://www.ncbi.nlm.nih.gov/pubmed/20058009
http://dx.doi.org/10.1007/s00280-009-1234-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921053/
https://www.ncbi.nlm.nih.gov/pubmed/20058009
http://dx.doi.org/10.1007/s00280-009-1234-z

Ejemplares similares